1. Home
  2. WEN vs ANAB Comparison

WEN vs ANAB Comparison

Compare WEN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wendy's Company (The)

WEN

Wendy's Company (The)

HOLD

Current Price

$7.88

Market Cap

1.4B

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$59.54

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEN
ANAB
Founded
1969
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2000
2015

Fundamental Metrics

Financial Performance
Metric
WEN
ANAB
Price
$7.88
$59.54
Analyst Decision
Hold
Buy
Analyst Count
22
12
Target Price
$8.84
$71.67
AVG Volume (30 Days)
11.8M
557.3K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
8.28%
N/A
EPS Growth
N/A
91.02
EPS
0.12
N/A
Revenue
$2,176,891,000.00
$234,603,000.00
Revenue This Year
$2.26
N/A
Revenue Next Year
$0.94
$52.14
P/E Ratio
$64.92
N/A
Revenue Growth
N/A
157.01
52 Week Low
$6.37
$17.11
52 Week High
$12.51
$73.30

Technical Indicators

Market Signals
Indicator
WEN
ANAB
Relative Strength Index (RSI) 57.99 44.72
Support Level $7.84 $53.46
Resistance Level $8.54 $67.69
Average True Range (ATR) 0.38 4.31
MACD 0.05 -0.81
Stochastic Oscillator 72.95 19.47

Price Performance

Historical Comparison
WEN
ANAB

About WEN Wendy's Company (The)

The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: